Targeting the Menin–KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success.

Clinical Lymphoma, Myeloma and Leukemia · Published 2026-08-01 · DOI 10.1016/j.clml.2026.07.019

Authors (2)

Claudia Simio, Alessandra Vatteroni

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Simio, C., Vatteroni, A. (2026). Targeting the Menin–KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success.. Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.07.019

Related articles

• The role of menin inhibitors in acute myeloid leukemia · Current Opinion in Oncology · 2025 · Cites or is cited by this article
• A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias · Journal of Hematology & Oncology · 2025 · Cites or is cited by this article
• The promise of menin inhibitors: from approval to triplet regimens · Hematology (United States) · 2025 · Cites or is cited by this article
• KMT2A-Partial Tandem Duplication associates with leukemia transformation in myelodysplastic syndrome · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
• Bispecific Antibody Therapy With Elranatamab for Refractory Waldenström Macroglobulinemia: A Case Report · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
• Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
• Treatment modalities and the impact of granulocyte colony-stimulating factor in AML patients treated with venetoclax and azacitidine: A DATAML registry study · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
• Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
• SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
• SOHO State of the Art Updates and Next Questions | Best of Stem Cell Transplant: Recent Advances in Allogeneic Hematopoietic Cell Transplantation · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal